Price movement over the last 24 hours
Alcon AG vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $27.34. The key difference: Alcon AG pays a 0.54% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | FNGU | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $92.22 | $36.15 |
52-Week Low | $62.02 | $13.73 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
FNGU is a leveraged exchange-traded note tracking the FANG+ Index, currently trading at $27.39, up 3.4% over the past day. Technical indicators show a bullish trend with strong moving average signals, though oscillators are neutral and short-term RSI suggests caution. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the risks of its 3x leverage structure.
The outlook for FNGU is highly speculative, offering amplified exposure to major tech stocks but carrying significant decay and volatility risks. Investment opportunity exists for aggressive traders betting on sustained tech sector strength, while the primary risk is rapid capital erosion during market downturns or flat periods, as evidenced by recent performance gaps versus the underlying index.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →